Home » Stocks » LPCN

Lipocine Inc. (LPCN)

Stock Price: $1.46 USD 0.04 (2.82%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $1.41 -0.05 (-3.43%) Apr 16, 7:28 PM
Market Cap 128.90M
Revenue (ttm) n/a
Net Income (ttm) -20.96M
Shares Out 55.69M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $1.46
Previous Close $1.42
Change ($) 0.04
Change (%) 2.82%
Day's Open 1.40
Day's Range 1.35 - 1.47
Day's Volume 1,332,970
52-Week Range 0.49 - 2.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Reddit stocks -- and in particular Reddit penny stocks -- are some of the riskiest shares out there. Yet, investors could make out big with some of the names on this list.

Other stocks mentioned: GME, OGI, SNDL, SVRA, YVR, ZOM
3 weeks ago - InvestorPlace

Amid risk-on sentiment, penny stocks are surging higher today as investors seek to grab the higher upside these small-cap stocks provide. The post Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and...

Other stocks mentioned: AREC, ONTX, TNXP, ZCMD
1 month ago - InvestorPlace

SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...

1 month ago - PRNewsWire

SALT LAKE CITY, March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results fo...

1 month ago - PRNewsWire

SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of an unde...

2 months ago - PRNewsWire

SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial...

3 months ago - PRNewsWire

SALT LAKE CITY, Dec. 30, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling ...

3 months ago - PRNewsWire

SALT LAKE CITY, Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge William C....

3 months ago - PRNewsWire

LPCN's long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval.

4 months ago - Seeking Alpha

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...

4 months ago - PRNewsWire

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent co...

4 months ago - PRNewsWire

SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...

4 months ago - PRNewsWire

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and o...

4 months ago - Insider Monkey

Lipocine is about to report data from its clinical study on whether TLANDO can restore testosterone levels in hypogonadal men without the dose titration requirement on November 9, 2020. Low baseline tes...

5 months ago - Seeking Alpha

SALT LAKE CITY, Nov. 6, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and...

5 months ago - PRNewsWire

SALT LAKE CITY, Aug. 28, 2020 /PRNewswire/ -- Lipocine Inc.

7 months ago - PRNewsWire

SALT LAKE CITY, Aug. 6, 2020 /PRNewswire/ -- Lipocine Inc.

8 months ago - PRNewsWire

SALT LAKE CITY, Aug. 3, 2020 /PRNewswire/ -- Lipocine Inc.

8 months ago - PRNewsWire

SALT LAKE CITY, July 13, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received ...

9 months ago - PRNewsWire

SALT LAKE CITY, May 15, 2020 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for...

11 months ago - PRNewsWire

Lipocine Inc. (NASDAQ: LPCN) shares absolutely plummeted on Monday after the firm announced that it received a Complete Response Letter (CRL) from the U.S.

1 year ago - 24/7 Wall Street

Lipocine Inc (NASDAQ: LPCN) shares are tumbling to record lows after an adverse FDA verdict on its lead drug Tlando, previously known as LPCN 1021.

1 year ago - Benzinga

Shares of Lipocine Inc. LPCN, -2.50% plummeted 67% toward a record low, and to pace all premarket losers, after the biopharmaceutical company said the Food and Drug Administration indicated that its New...

1 year ago - Market Watch

Lipocine Inc is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate.

2 years ago - Benzinga

About LPCN

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailabili... [Read more...]

Industry
Biotechnology
CEO
Mahesh Patel
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
LPCN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Lipocine stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 265.07% from the latest price.

Price Target
$5.33
(265.07% upside)
Analyst Consensus: Buy